GSK to reimburse tuition fees for UK trainees
pharmafile | March 3, 2011 | News story | Business Services, Research and Development, Sales and Marketing | GSK, GlaxoSmithKline, UK science, careers, graduate, graduate recruitment
GlaxoSmithKline is set to reimburse UK university tuition fees paid by its trainees from 2012.
Each year, GSK recruits between 50-100 undergraduate students from various academic disciplines into its UK graduate training programmes or other roles within the company.
Successful applicants are already offered highly competitive compensation packages but GSK hopes the further incentive will increase its desirability to graduates.
Undergraduate students in the UK already pay £3,000 per year, typically for a three-year degree course, and this is set to double to £6,000 per year from 2012.
Universities can raise fees to a maximum of £9,000 per year if they sign up to a scheme to assist access for disadvantaged students, and Oxford, Cambridge, Imperial and Exeter universities have already done so.
Mr Witty told Sky News the scheme was not only for scientists, chemists and pharmacists, but for lawyers, economists and “the very best” graduates who could help GSK.
“The biggest reason we are doing this is that we want to get the absolute best possible graduates we can to work for GSK,” he told the programme.
“This is a great way for us to try and ensure we get that next brilliant scientist,” he said but acknowledged it could start a “bidding war” for the best graduates.
GSK said its new reimbursement programme would start from September 2012, when the new student fee structure comes into effect.
Students’ fee payments will be reimbursed when they begin full employment with GSK and will be conditional on the employee remaining with the company for a minimum of two years.
Ben Adams
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination …
